Terms: = Ovarian cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Treatment
209 results:
1. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-pd-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
2. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
3. Linear IgA bullous dermatosis associated with immunotherapy.
Momin B; Nguyen TF; Glade D; Messer A
Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478666
[TBL] [Abstract] [Full Text] [Related]
4. New windows of surgical opportunity for gynecological cancers in the era of targeted therapies.
Peters I; Marchetti C; Scambia G; Fagotti A
Int J Gynecol Cancer; 2024 Mar; 34(3):352-362. PubMed ID: 38438181
[TBL] [Abstract] [Full Text] [Related]
5. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
[TBL] [Abstract] [Full Text] [Related]
6. Metabolic-Related Gene Prognostic Index for Predicting Prognosis, Immunotherapy Response, and Candidate Drugs in ovarian cancer.
Guo S; Liu Y; Sun Y; Zhou H; Gao Y; Wang P; Zhi H; Zhang Y; Gan J; Ning S
J Chem Inf Model; 2024 Feb; 64(3):1066-1080. PubMed ID: 38238993
[TBL] [Abstract] [Full Text] [Related]
7. A Microfluidics Approach for ovarian cancer Immune Monitoring in an Outpatient Setting.
Libbrecht S; Vankerckhoven A; de Wijs K; Baert T; Thirion G; Vandenbrande K; Van Gorp T; Timmerman D; Coosemans A; Lagae L
Cells; 2023 Dec; 13(1):. PubMed ID: 38201211
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer.
Chen S; Li X; Ao W
BMC Womens Health; 2024 Jan; 24(1):6. PubMed ID: 38166898
[TBL] [Abstract] [Full Text] [Related]
9. PD-L1 and pd-1 Expression in Early Stage Uterine Endometrioid Carcinoma.
An HJ; Yang JW; Kim MH; Song DH
In Vivo; 2024; 38(1):246-252. PubMed ID: 38148043
[TBL] [Abstract] [Full Text] [Related]
10. Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8
Luan X; Lei T; Fang J; Liu X; Fu H; Li Y; Chu W; Jiang P; Tong C; Qi H; Fu Y
Mol Ther; 2024 Feb; 32(2):469-489. PubMed ID: 38098230
[TBL] [Abstract] [Full Text] [Related]
11. Hypoxic 3D Tumor Model for Evaluating of CAR-T Cell Therapy In Vitro.
Oh JM; Shen K
Methods Mol Biol; 2024; 2748():119-134. PubMed ID: 38070112
[TBL] [Abstract] [Full Text] [Related]
12. The prognostic significance of tumor-immune microenvironment in ascites of patients with high-grade serous carcinoma.
Miceska S; Skof E; Bucek S; Kuhar CG; Gasljevic G; Smrkolj S; Prevodnik VK
Radiol Oncol; 2023 Dec; 57(4):493-506. PubMed ID: 38038414
[TBL] [Abstract] [Full Text] [Related]
13. Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab treatment in Patients with Advanced ovarian cancer.
Kos FJ; Frankel P; Cristea M; Eng M; Tinsley R; Dempsey S; Ruel N; Stewart D; Dellinger TH; Diamond DJ
Cancer Res Commun; 2023 Dec; 3(12):2585-2595. PubMed ID: 38032111
[TBL] [Abstract] [Full Text] [Related]
14. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
15. Machine learning-derived identification of prognostic signature for improving prognosis and drug response in patients with ovarian cancer.
Huan Q; Cheng S; Ma HF; Zhao M; Chen Y; Yuan X
J Cell Mol Med; 2024 Jan; 28(1):e18021. PubMed ID: 37994489
[TBL] [Abstract] [Full Text] [Related]
16. miR-124 delivered by BM-MSCs-derived exosomes targets MCT1 of tumor-infiltrating Treg cells and improves ovarian cancer immunotherapy.
Gao T; Lin YQ; Ye HY; Lin WM
Neoplasma; 2023 Dec; 70(6):713-721. PubMed ID: 37962863
[TBL] [Abstract] [Full Text] [Related]
17. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade.
Luo Y; Shreeder B; Jenkins JW; Shi H; Lamichhane P; Zhou K; Bahr DA; Kurian S; Jones KA; Daum JI; Dutta N; Necela BM; Cannon MJ; Block MS; Knutson KL
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37918918
[TBL] [Abstract] [Full Text] [Related]
18. Identification of the functional PD-L1 interface region responsible for pd-1 binding and initiation of pd-1 signaling.
Carter R; Alanazi F; Sharp A; Roman J; Luchini A; Liotta L; Paige M; Brown AM; Haymond A
J Biol Chem; 2023 Dec; 299(12):105353. PubMed ID: 37858677
[TBL] [Abstract] [Full Text] [Related]
19. Frequency of peripheral pd-1
Park J; Kim JC; Lee M; Lee J; Kim YN; Lee YJ; Kim S; Kim SW; Park SH; Lee JY
Br J Cancer; 2023 Nov; 129(11):1841-1851. PubMed ID: 37821637
[TBL] [Abstract] [Full Text] [Related]
20. Identification of two immune subtypes and four hub immune-related genes in ovarian cancer through multiple analysis.
Tang Q; Zhang H; Tang R
Medicine (Baltimore); 2023 Oct; 102(40):e35246. PubMed ID: 37800814
[TBL] [Abstract] [Full Text] [Related]
[Next]
